Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
74
GHRS Quote, Financials, Valuation and Earnings
Last price:
$15.57
Seasonality move
:
25.99%
Day range:
$14.17 - $18.17
52-week range:
$7.98 - $20.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.82x
Volume:
1.8M
Avg. volume:
511.3K
1-year change:
97.04%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$0.73
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GHRS
GH Research Plc
|
-- | -$0.27 | -- | -62.11% | $32.61 |
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | -18% | -100% | $12.00 |
|
ITRM
Iterum Therapeutics Plc
|
$505K | -$0.24 | -- | -49.47% | $5.50 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.41 | 6.17% | 106.38% | $213.00 |
|
PRTA
Prothena Corp. Plc
|
$666.7K | -$0.46 | -68.6% | -57.29% | $20.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GHRS
GH Research Plc
|
$17.95 | $32.61 | $1.1B | -- | $0.00 | 0% | -- |
|
AMRN
Amarin Corp. Plc
|
$14.03 | $12.00 | $291.7M | -- | $0.00 | 0% | 7.32x |
|
ITRM
Iterum Therapeutics Plc
|
$0.36 | $5.50 | $16M | -- | $0.00 | 0% | 33.71x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$169.37 | $213.00 | $10.3B | 15.09x | $0.00 | 0% | 2.49x |
|
PRTA
Prothena Corp. Plc
|
$9.13 | $20.33 | $491.5M | -- | $0.00 | 0% | 41.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GHRS
GH Research Plc
|
0.2% | 1.978 | 0.07% | 27.72x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 3.053 | 1.98% | 2.35x |
|
ITRM
Iterum Therapeutics Plc
|
128.01% | 1.048 | 112.75% | 1.78x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.175 | 67.81% | 1.24x |
|
PRTA
Prothena Corp. Plc
|
2.99% | 1.301 | 1.73% | 6.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GHRS
GH Research Plc
|
-$89K | -$16.5M | -16.82% | -16.86% | -- | -$14.5M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
ITRM
Iterum Therapeutics Plc
|
$15K | -$7.7M | -98.23% | -- | -1982.31% | -$7.9M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
PRTA
Prothena Corp. Plc
|
$1.5M | -$39.8M | -65.85% | -67.47% | -1646.42% | -$43.2M |
GH Research Plc vs. Competitors
-
Which has Higher Returns GHRS or AMRN?
Amarin Corp. Plc has a net margin of -- compared to GH Research Plc's net margin of -15.58%. GH Research Plc's return on equity of -16.86% beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research Plc-- -$0.23 $292M AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About GHRS or AMRN?
GH Research Plc has a consensus price target of $32.61, signalling upside risk potential of 81.66%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -14.47%. Given that GH Research Plc has higher upside potential than Amarin Corp. Plc, analysts believe GH Research Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research Plc5 1 0 AMRNAmarin Corp. Plc0 1 1 -
Is GHRS or AMRN More Risky?
GH Research Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.8%.
-
Which is a Better Dividend Stock GHRS or AMRN?
GH Research Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or AMRN?
GH Research Plc quarterly revenues are --, which are smaller than Amarin Corp. Plc quarterly revenues of $49.4M. GH Research Plc's net income of -$14M is lower than Amarin Corp. Plc's net income of -$7.7M. Notably, GH Research Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research Plc is -- versus 7.32x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research Plc-- -- -- -$14M AMRNAmarin Corp. Plc7.32x -- $49.4M -$7.7M
-
Which has Higher Returns GHRS or ITRM?
Iterum Therapeutics Plc has a net margin of -- compared to GH Research Plc's net margin of -2302.31%. GH Research Plc's return on equity of -16.86% beat Iterum Therapeutics Plc's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research Plc-- -$0.23 $292M ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M -
What do Analysts Say About GHRS or ITRM?
GH Research Plc has a consensus price target of $32.61, signalling upside risk potential of 81.66%. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 1432.03%. Given that Iterum Therapeutics Plc has higher upside potential than GH Research Plc, analysts believe Iterum Therapeutics Plc is more attractive than GH Research Plc.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research Plc5 1 0 ITRMIterum Therapeutics Plc1 0 0 -
Is GHRS or ITRM More Risky?
GH Research Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.867, suggesting its more volatile than the S&P 500 by 186.66%.
-
Which is a Better Dividend Stock GHRS or ITRM?
GH Research Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research Plc pays -- of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or ITRM?
GH Research Plc quarterly revenues are --, which are smaller than Iterum Therapeutics Plc quarterly revenues of $390K. GH Research Plc's net income of -$14M is lower than Iterum Therapeutics Plc's net income of -$9M. Notably, GH Research Plc's price-to-earnings ratio is -- while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research Plc is -- versus 33.71x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research Plc-- -- -- -$14M ITRMIterum Therapeutics Plc33.71x -- $390K -$9M
-
Which has Higher Returns GHRS or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -- compared to GH Research Plc's net margin of 22.33%. GH Research Plc's return on equity of -16.86% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research Plc-- -$0.23 $292M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About GHRS or JAZZ?
GH Research Plc has a consensus price target of $32.61, signalling upside risk potential of 81.66%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 25.76%. Given that GH Research Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe GH Research Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research Plc5 1 0 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is GHRS or JAZZ More Risky?
GH Research Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.796%.
-
Which is a Better Dividend Stock GHRS or JAZZ?
GH Research Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or JAZZ?
GH Research Plc quarterly revenues are --, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. GH Research Plc's net income of -$14M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, GH Research Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research Plc is -- versus 2.49x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research Plc-- -- -- -$14M JAZZJazz Pharmaceuticals Plc2.49x 15.09x $1.1B $251.4M
-
Which has Higher Returns GHRS or PRTA?
Prothena Corp. Plc has a net margin of -- compared to GH Research Plc's net margin of -1513.09%. GH Research Plc's return on equity of -16.86% beat Prothena Corp. Plc's return on equity of -67.47%.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research Plc-- -$0.23 $292M PRTAProthena Corp. Plc60.95% -$0.68 $304.1M -
What do Analysts Say About GHRS or PRTA?
GH Research Plc has a consensus price target of $32.61, signalling upside risk potential of 81.66%. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.33 which suggests that it could grow by 122.71%. Given that Prothena Corp. Plc has higher upside potential than GH Research Plc, analysts believe Prothena Corp. Plc is more attractive than GH Research Plc.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research Plc5 1 0 PRTAProthena Corp. Plc2 2 0 -
Is GHRS or PRTA More Risky?
GH Research Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.093, suggesting its less volatile than the S&P 500 by 109.25%.
-
Which is a Better Dividend Stock GHRS or PRTA?
GH Research Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research Plc pays -- of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or PRTA?
GH Research Plc quarterly revenues are --, which are smaller than Prothena Corp. Plc quarterly revenues of $2.4M. GH Research Plc's net income of -$14M is higher than Prothena Corp. Plc's net income of -$36.5M. Notably, GH Research Plc's price-to-earnings ratio is -- while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research Plc is -- versus 41.70x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research Plc-- -- -- -$14M PRTAProthena Corp. Plc41.70x -- $2.4M -$36.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
